Radioactive iodine uptake test

Source: Wikipedia, the free encyclopedia.
Radioactive iodine uptake test
Thyroid scan with Iodine-123 for evaluation of hyperthyroidism.
SynonymsRAIU test
ICD-9-CM92.01
OPS-301 code3-701

The radioactive iodine uptake test is a type of scan used in the diagnosis of thyroid problems, particularly hyperthyroidism. It is entirely different from radioactive iodine therapy (RAI therapy), which uses much higher doses to destroy cancerous cells. The RAIU test is also used as a follow-up to RAI therapy to verify that no thyroid cells survived, which could still be cancerous.[1]

The patient swallows

μCi) of 131I iodide, or 3.7–7.4 MBq (100–200 μCi) of 123I iodide.[2] The RAIU test is a reliable measurement when using a dedicated probe with a reproducibility of 1 percent and a 95%-least-significant-change of 3 percent.[3]

The normal uptake is between 15 and 25 percent, but this may be forced down if, in the meantime, the patient has eaten foods high in iodine, such as dairy products and seafood.[4] Low uptake suggests thyroiditis, high uptake suggests Graves' disease,[5] and unevenness in uptake suggests the presence of a nodule.[citation needed]

123I has a shorter

beta radiation.[7]

Contraindications

The test is inappropriate for patients who are pregnant or breastfeeding.[5]

Additional images

  • Thyroid scintigraphy
    Thyroid scintigraphy

LMP BNUKSEA 4000+60000

References

  1. ^ [1] ThyCa: Thyroid Cancer Survivors' Association, Inc., Radioactive Iodine (RAI).
  2. ISBN 978-0-8247-2876-2. {{cite book}}: |journal= ignored (help
    )
  3. .
  4. ^ M. Sara Rosenthal. The Thyroid Sourcebook. McGraw-Hill, 2008. Page 140.
  5. ^ a b WebMD article on RAIU test.
  6. . Retrieved 18 July 2011.
  7. . Retrieved 18 July 2011.